Acetal phosphatidic acids: novel platelet aggregating agents
Authors:
- 1 May 1983
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 79 (1) , 157-166
Abstract
Palmitaldehyde, olealdehyde and linolealdehyde acetal phosphatidic acids induced rapid shape change and dose‐dependent biphasic aggregation of human platelets in platelet‐rich plasma; aggregation was reversible at low doses and irreversible at high doses of the acetal phosphatidic acids. The palmitaldehyde congener elicited monophasic dose‐dependent aggregation of sheep platelets in platelet‐rich plasma. The threshold concentration for palmitaldehyde acetal phosphatidic acid (PGAP)‐induced platelet aggregation was 2.5–5 μM for human platelets and 0.25–0.5 μM for sheep platelets. PGAP was 4–5 times as potent versus human platelets as the olealdehyde and linolealdehyde acetal phosphatidic acids, which were equipotent. PGAP‐induced irreversible aggregation of [14C]‐5‐hydroxytryptamine ([14C]‐5‐HT)‐labelled human platelets in platelet‐rich plasma was accompanied by release of 44.0 ± 2.4% (s.e.) of the platelet [14C]‐5‐HT; reversible aggregation was not associated with release. In contrast, PGAP‐induced release of [14C]‐5‐HT‐labelled sheep platelets was dose‐dependent. The adenosine diphosphate (ADP) antagonist, 2‐methylthio‐AMP, and the cyclo‐oxygenase inhibitor, aspirin, abolished PGAP‐induced second phase aggregation and release in human platelets but did not affect the first, reversible, phase of aggregation. Both the first and second phases of PGAP‐induced aggregation were abolished by chlorpromazine, by the phospholipase A2 inhibitor, mepacrine, and by nmolar concentrations of prostaglandin E1 (PGE1); these agents abolished the second, but not the first phase of ADP‐induced aggregation. The related phospholipids, lecithin, lysolecithin and phosphatidic acid, at < 100 μM, neither induced aggregation of human platelets in platelet‐rich plasma, nor modified PGAP‐induced aggregation; 1‐palmityl lysophosphatidic acid elicited aggregation of human platelets at a threshold concentration of 100 μM. It is concluded that the acetal phosphatidic acids induce platelet aggregation per se by direct action at the platelet membrane, and that the acetal function is of primary importance in their potent platelet‐stimulating activity. Moreover, as the acetal phosphatidic acids are the major components of the smooth muscle‐contracting acidic phospholipid tissue extract ‘Darmstoff’ (Vogt, 1949), their potent platelet‐aggregating properties may be of physiological or pathological significance.Keywords
This publication has 26 references indexed in Scilit:
- Effects of vinblastine on malondialdehyde formation, serotonin release and aggregation in human plateletsEuropean Journal of Pharmacology, 1982
- New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixturesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981
- Decreased viscosity of human erythrocyte suspension induced by chlorpromazine and isoxsuprineBiochemical Pharmacology, 1981
- Mechanisms of inhibition of phospholipase A2Biochemical Pharmacology, 1980
- Regulation of the intracellular calcium level in human blood platelets: Cyclic adenosine 3′,5′-monophosphate dependent phosphorylation of a 22 000 dalton component in isolated Ca2+-accumulating vesiclesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1979
- Further characterization of calcium-accumulating vesicles from human blood plateletsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1978
- New inhibitors of platelet aggregation. 5'-Phosphate, 5'-phosphorothioate, and 5'-O-sulfamoyl derivatives of 2-substituted adenosine analogsJournal of Medicinal Chemistry, 1978
- Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3′,5′-cyclic monophosphate and protein kinaseBiochimica et Biophysica Acta (BBA) - Biomembranes, 1977
- Selective inhibition by mepacrine of the release of “rabbit aorta contracting substance” evoked by the administration of bradykininJournal of Pharmacy and Pharmacology, 1972
- Pharmacologically active acidic phospholipids and glycolipidsBiochemical Pharmacology, 1963